NIA-funded researchers have found that people who took the drug sildenafil, sold under the brand names Viagra and Revatio, were less likely to develop Alzheimer’s disease (AD). Sildenafil also enhanced growth and reduced Alzheimer’s biomarkers in cultured human neurons.
A commonly reported symptom of Covid-19 infection has been loss of taste and smell. NIAID-funded researchers have found another sensory connection: SARS-CoV-2 can infect inner ear cells.
A clinical trial has found the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.
New evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen can improve how long some younger people with a specific form of diffuse large B-cell lymphoma (DLBCL) live.
Researchers found that a neglected antibiotic called hygromycin A selectively kills Borelliella burgdorferi, the bacteria that cause Lyme disease. The antibiotic was able to treat Lyme disease in mice without disrupting the microbiome.
Research suggests that newborns can reap some of the same health benefits that others get from consistent, quality shut-eye.
NIH, FDA, 10 pharmaceutical companies and 5 nonprofit organizations have partnered to accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.
A commonly available FDA-approved oral diuretic pill may be a potential candidate for an Alzheimer’s disease treatment for those who are at genetic risk, according to findings published in Nature Aging.
Researchers report that a booster dose of the Moderna Covid-19 vaccine given to rhesus macaques enhanced their immune response, providing protection against all known circulating SARS-CoV-2 variants.
Overdose deaths involving methamphetamine nearly tripled from 2015 to 2019 among people ages 18-64 in the U.S., according to a NIDA study published in JAMA Psychiatry.